Aripiprazole
- Generic Name
- Aripiprazole
- Brand Names
- Abilify, Aripiprazole Mylan Pharma (previously Aripiprazole Pharmathen), Abilify Maintena, Aripiprazole Accord, Aripiprazole Sandoz, Aripiprazole Zentiva
- Drug Type
- Small Molecule
- Chemical Formula
- C23H27Cl2N3O2
- CAS Number
- 129722-12-9
- Unique Ingredient Identifier
- 82VFR53I78
- Background
Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects through agonism of dopaminergic and 5-HT1A ...
- Indication
Aripiprazole is indicated for the treatment of acute manic and mixed episodes associated with bipolar I disorder, irritability associated with autism spectrum disorder, schizophrenia, and Tourette's disorder. It is also used as an adjunctive treatment of major depressive disorder.[L45859 An injectable formulation of aripiprazole is indicated for agitation as...
- Associated Conditions
- Agitation, Bipolar 1 Disorder, Irritability, Major Depressive Disorder (MDD), Mixed manic depressive episode, Psychosis, Psychotic Depression, Schizophrenia, Tourette's Disorder (TD), Acute Manic episode
- Associated Therapies
- Monotherapy
Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
- First Posted Date
- 2004-03-30
- Last Posted Date
- 2013-11-11
- Target Recruit Count
- 370
- Registration Number
- NCT00080327
- Locations
- 🇺🇸
Bristol-Meyers Squibb Call Center, Wallingford, Connecticut, United States
Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depression Episode
- First Posted Date
- 2004-03-30
- Last Posted Date
- 2013-11-11
- Target Recruit Count
- 400
- Registration Number
- NCT00080314
- Locations
- 🇺🇸
Local Institution, Bellevue, Washington, United States
🇺🇸Local Insstitution, Honolulu, Hawaii, United States
Study of Aripiprazole in the Treatment of Patients With Acute Symptoms of Bipolar Disorder
- Conditions
- Locations
- 🇦🇷
Local Institution, Mendoza, Argentina
Switching Medication to Treat Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2002-09-05
- Last Posted Date
- 2016-04-28
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 219
- Registration Number
- NCT00044655
Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type
- Conditions
- Locations
- 🇺🇸
Local Institution, Milwaukee, Wisconsin, United States
Study of Aripiprazole in Patients With a History of Bipolar Disorder
- Conditions
- Locations
- 🇺🇸
Local Institution, San Antonio, Texas, United States
Broad Effectiveness: Study With Aripiprazole
- Conditions
- First Posted Date
- 2002-05-10
- Last Posted Date
- 2013-11-11
- Target Recruit Count
- 444
- Registration Number
- NCT00036361
- Locations
- 🇺🇸
Local Institution, Wallingford, Connecticut, United States
Study of Aripiprazole in the Treatment of Patients With Acute Symptoms in Bipolar Disorder
- Conditions
- Locations
- 🇺🇸
Local Institution, Bellevue, Washington, United States
Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type
- Conditions
- Locations
- 🇺🇸
Local Institution, Seattle, Washington, United States
Study of Alternate Formulation of Aripiprazole in Agitated Patients With Schizophrenic Disorders
- Conditions
- Locations
- 🇺🇸
Local Instituton, Hoffman Estates, Illinois, United States
🇺🇸Local Institution, Milwaukee, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.